Lexeo Therapeutics, Inc. (LXEO)
- Previous Close
12.16 - Open
12.33 - Bid 12.25 x 100
- Ask 12.66 x 100
- Day's Range
11.98 - 12.85 - 52 Week Range
9.00 - 22.33 - Volume
376,712 - Avg. Volume
109,223 - Market Cap (intraday)
411.845M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.40
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
www.lexeotx.comRecent News: LXEO
Performance Overview: LXEO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LXEO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LXEO
Valuation Measures
Market Cap
411.84M
Enterprise Value
302.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.63
Enterprise Value/Revenue
416.34
Enterprise Value/EBITDA
-4.69
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.15%
Return on Equity (ttm)
-71.54%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-66.39M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
121.47M
Total Debt/Equity (mrq)
10.25%
Levered Free Cash Flow (ttm)
-35.22M